Deborah J. Steiner

General Practice

4 Rose Ave
Great Neck, NY 11021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Comment on: Use of Plerixafor for Short-Term Management of Leukopenia in a Pediatric Patient With WHIM Syndrome.

Comment on: Use of Plerixafor for Short-Term Management of Leukopenia in a Pediatric Patient With WHIM Syndrome.

Journal: Pediatric blood & cancer

Published: April 09, 2025

Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement.

Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement.

Journal: Pain

Published: August 09, 2023

Patient engagement in designing, conducting, and disseminating clinical pain research: IMMPACT recommended considerations.

Patient engagement in designing, conducting, and disseminating clinical pain research: IMMPACT recommended considerations.

Journal: Pain

Published: March 27, 2023

Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement.

Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement.

Journal: Pain

Published: February 10, 2022

Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations.

Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations.

Journal: Pain

Published: January 20, 2021

Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria.

Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria.

Journal: Neurology

Published: June 10, 2020

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Journal: The Lancet. Neurology

Published: October 23, 2017

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Journal: Therapeutic advances in neurological disorders

Published: January 21, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026